180 related articles for article (PubMed ID: 19412725)
1. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
Hassin-Baer S; Laitman Y; Azizi E; Molchadski I; Galore-Haskel G; Barak F; Cohen OS; Friedman E
J Neurol; 2009 Mar; 256(3):483-7. PubMed ID: 19412725
[TBL] [Abstract][Full Text] [Related]
2. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
3. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
[TBL] [Abstract][Full Text] [Related]
4. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
[TBL] [Abstract][Full Text] [Related]
5. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.
Thaler A; Ash E; Gan-Or Z; Orr-Urtreger A; Giladi N
J Neural Transm (Vienna); 2009 Nov; 116(11):1473-82. PubMed ID: 19756366
[TBL] [Abstract][Full Text] [Related]
6. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
7. Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.
Marder K; Wang Y; Alcalay RN; Mejia-Santana H; Tang MX; Lee A; Raymond D; Mirelman A; Saunders-Pullman R; Clark L; Ozelius L; Orr-Urtreger A; Giladi N; Bressman S;
Neurology; 2015 Jul; 85(1):89-95. PubMed ID: 26062626
[TBL] [Abstract][Full Text] [Related]
8. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.
Clark LN; Wang Y; Karlins E; Saito L; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
Neurology; 2006 Nov; 67(10):1786-91. PubMed ID: 17050822
[TBL] [Abstract][Full Text] [Related]
9. Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.
Bar-Shira A; Hutter CM; Giladi N; Zabetian CP; Orr-Urtreger A
Neurogenetics; 2009 Oct; 10(4):355-8. PubMed ID: 19283415
[TBL] [Abstract][Full Text] [Related]
10. Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Alcalay RN; Mirelman A; Saunders-Pullman R; Tang MX; Mejia Santana H; Raymond D; Roos E; Orbe-Reilly M; Gurevich T; Bar Shira A; Gana Weisz M; Yasinovsky K; Zalis M; Thaler A; Deik A; Barrett MJ; Cabassa J; Groves M; Hunt AL; Lubarr N; San Luciano M; Miravite J; Palmese C; Sachdev R; Sarva H; Severt L; Shanker V; Swan MC; Soto-Valencia J; Johannes B; Ortega R; Fahn S; Cote L; Waters C; Mazzoni P; Ford B; Louis E; Levy O; Rosado L; Ruiz D; Dorovski T; Pauciulo M; Nichols W; Orr-Urtreger A; Ozelius L; Clark L; Giladi N; Bressman S; Marder KS
Mov Disord; 2013 Dec; 28(14):1966-71. PubMed ID: 24243757
[TBL] [Abstract][Full Text] [Related]
11. The LRRK2 G2019S mutation in a series of Argentinean patients with Parkinson's disease: clinical and demographic characteristics.
Gatto EM; Parisi V; Converso DP; Poderoso JJ; Carreras MC; Martí-Massó JF; Paisán-Ruiz C
Neurosci Lett; 2013 Mar; 537():1-5. PubMed ID: 23340200
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of Parkinson's disease among Jewish Ethnic groups in Israel.
Djaldetti R; Hassin-Baer S; Farrer MJ; Vilariño-Güell C; Ross OA; Kolianov V; Yust-Katz S; Treves TA; Barhum Y; Hulihan M; Melamed E
J Neural Transm (Vienna); 2008 Sep; 115(9):1279-84. PubMed ID: 18665323
[TBL] [Abstract][Full Text] [Related]
13. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
Inzelberg R; Cohen OS; Aharon-Peretz J; Schlesinger I; Gershoni-Baruch R; Djaldetti R; Nitsan Z; Ephraty L; Tunkel O; Kozlova E; Inzelberg L; Kaplan N; Fixler Mehr T; Mory A; Dagan E; Schechtman E; Friedman E; Hassin-Baer S
Neurology; 2012 Mar; 78(11):781-6. PubMed ID: 22323743
[TBL] [Abstract][Full Text] [Related]
14. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.
Eblan MJ; Scholz S; Stubblefield B; Gutti U; Goker-Alpan O; Hruska KS; Singleton AB; Sidransky E
Neurosci Lett; 2006 Aug; 404(1-2):163-5. PubMed ID: 16781064
[TBL] [Abstract][Full Text] [Related]
15. Age at Onset of Parkinson's Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations.
Yahalom G; Rigbi A; Israeli-Korn S; Krohn L; Rudakou U; Ruskey JA; Benshimol L; Tsafnat T; Gan-Or Z; Hassin-Baer S; Greenbaum L
J Parkinsons Dis; 2020; 10(3):1123-1132. PubMed ID: 32310186
[TBL] [Abstract][Full Text] [Related]
16. LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.
Saunders-Pullman R; Barrett MJ; Stanley KM; Luciano MS; Shanker V; Severt L; Hunt A; Raymond D; Ozelius LJ; Bressman SB
Mov Disord; 2010 Nov; 25(15):2536-41. PubMed ID: 20818610
[TBL] [Abstract][Full Text] [Related]
17. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
[TBL] [Abstract][Full Text] [Related]
18. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans.
Lesage S; Patin E; Condroyer C; Leutenegger AL; Lohmann E; Giladi N; Bar-Shira A; Belarbi S; Hecham N; Pollak P; Ouvrard-Hernandez AM; Bardien S; Carr J; Benhassine T; Tomiyama H; Pirkevi C; Hamadouche T; Cazeneuve C; Basak AN; Hattori N; Dürr A; Tazir M; Orr-Urtreger A; Quintana-Murci L; Brice A;
Hum Mol Genet; 2010 May; 19(10):1998-2004. PubMed ID: 20197411
[TBL] [Abstract][Full Text] [Related]
20. Low-variance RNAs identify Parkinson's disease molecular signature in blood.
Chikina MD; Gerald CP; Li X; Ge Y; Pincas H; Nair VD; Wong AK; Krishnan A; Troyanskaya OG; Raymond D; Saunders-Pullman R; Bressman SB; Yue Z; Sealfon SC
Mov Disord; 2015 May; 30(6):813-21. PubMed ID: 25786808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
